Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 71 articles: HTML format

Single Articles

December 2025
1. PISTILLI B, Jhaveri K, Im SA, Pernas S, et al
   Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.
   Ann Oncol. 2025 Dec 23:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
2. ARORA A, Bhaskarane H, Tansir G, Bakhshi S, et al
   A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC
   Ann Oncol. 2025 Dec 22:S0923-7534(25)06335-5. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
3. GLUZ O, Kates R, Kuemmel S, Nitz U, et al
   A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
   Ann Oncol. 2025 Dec 20:S0923-7534(25)06333-1. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
4. SCHMID PS, McArthur HL, Cortes J, Xu B, et al
   Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.
   Ann Oncol. 2025 Dec 19:S0923-7534(25)06332-X. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
5. JHAVERI KL, Neven P, Casalnuovo ML, Kim SB, et al
   Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial.
   Ann Oncol. 2025 Dec 12:S0923-7534(25)06289-1. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   November 2025
6. HURVITZ SA, Loi S, O'Shaughnessy J, Okines AFC, et al
   Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06263-5. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
7. CABEL L, Berger F, Bachelot T, Pistilli B, et al
   Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06260-X. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
8. SAURA C, Cortes J, Modi S, Kim SB, et al
   Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06265-9. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
9. TOSS A, Blondeaux E, Tenedini E, Bonamici L, et al
   ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06262-3. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
10. GUTTERY DS, Shaw JA, Stebbing J
    Intercepting endocrine resistance in ER+/HER2- metastatic breast cancer: Insights from the PADA-1 trial.
    Ann Oncol. 2025 Nov 15:S0923-7534(25)06261-1. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    October 2025
11. MAYER EL, Bidard FC, Park YH, Janni W, et al
    Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
    Ann Oncol. 2025 Oct 20:S0923-7534(25)04949-X. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
12. HARBECK N, Modi S, Pusztai L, Ohno S, et al
    Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
    Ann Oncol. 2025 Oct 18:S0923-7534(25)04968-3. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
13. MAYER EL, Hlauschek D, Gnant M, O'Brien PJ, et al
    Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
    Ann Oncol. 2025 Oct 17:S0923-7534(25)04935-X. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
14. JOHNSTON S, Martin M, O'Shaughnessy J, Hegg R, et al
    Overall Survival with Abemaciclib in Early Breast Cancer.
    Ann Oncol. 2025 Oct 17:S0923-7534(25)04948-8. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
15. MAYER EL, Trapani D, Kim SE, Faggen M, et al
    TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
    Ann Oncol. 2025 Oct 17:S0923-7534(25)04932-4. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
16. MALORNI L, Tyekucheva S, Gombos A, Hasler-Strub U, et al
    Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
    Ann Oncol. 2025 Oct 16:S0923-7534(25)04963-4. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
17. GOETZ MP, Toi M, Huober J, Sohn J, et al
    Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
    Ann Oncol. 2025 Oct 15:S0923-7534(25)00851-8. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
18. BURSTEIN HJ, Curigliano G, Gnant M, Loibl S, et al
    Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer.
    Ann Oncol. 2025 Oct 8:S0923-7534(25)04718-0. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    September 2025
19. CHEN N, Freeman JQ, Yarlagadda S, Atmakuri A, et al
    Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer.
    Ann Oncol. 2025 Sep 17:S0923-7534(25)00922-6. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    August 2025
20. CONTE PF, Dieci MV, Bisagni G, Schmid P, et al
    A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.
    Ann Oncol. 2025 Aug 28:S0923-7534(25)00925-1. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
21. TRAPANI D, Martins-Branco D, Curigliano G, Gennari A, et al
    Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline.
    Ann Oncol. 2025 Aug 12:S0923-7534(25)00914-7. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
22. GRAESER M, Gluz O, Zu Eulenburg C, Kuemmel S, et al
    Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
    Ann Oncol. 2025 Aug 4:S0923-7534(25)00913-5. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    July 2025
23. VAN BAELEN K, Sawyer E, Van Cauwenberge J, Aftimos P, et al
    Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
    Ann Oncol. 2025 Jul 21:S0923-7534(25)00857-9. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
24. MAMANN A, Pradat Y, Bidard FC, Delaloge S, et al
    Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer.
    Ann Oncol. 2025 Jul 5:S0923-7534(25)00830-0. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
25. PROVENZANO L, Dieci MV, Curigliano G, Giuliano M, et al
    Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
    Ann Oncol. 2025;36:762-774.
    PubMed     Abstract available
    
    
    June 2025
26. HU Q, Yang X
    Navigating the Limits of Ribociclib in Early Breast Cancer: Questions from the NATALEE Trial.
    Ann Oncol. 2025 Jun 23:S0923-7534(25)00815-4. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
27. ZHU X, Zhu T, Gu X
    Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
    Ann Oncol. 2025 Jun 20:S0923-7534(25)00816-6. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
28. LOIBL S, Nekljudova V, Denkert C
    Reply to Letter to the Editor "Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B" by Sahin and Guven.
    Ann Oncol. 2025 Jun 10:S0923-7534(25)00167-X. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
29. ANDRE F, Tecson K, Egorov A
    Reply to Letter to the Editor: 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by Y. Liu & C. Zhang.
    Ann Oncol. 2025 Jun 10:S0923-7534(25)00193-0. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
30. TURNBULL C, Achatz MI, Balmana J, Castro E, et al
    Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.
    Ann Oncol. 2025 Jun 9:S0923-7534(25)00172-3. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    May 2025
31. LIU Y, Zhang C, Liu Y
    Letter to the editor 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by F. Andre et al.
    Ann Oncol. 2025 May 21:S0923-7534(25)00735-5. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
32. SAHIN TK, Guven DC
    Letter to the Editor - Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B.
    Ann Oncol. 2025 May 20:S0923-7534(25)00734-3. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    April 2025
33. AKAMANDISA MP, Boddicker NJ, Yadav S, Hu C, et al
    Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
    Ann Oncol. 2025 Apr 25:S0923-7534(25)00170-X. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
34. PAPAKONSTANTINOU A, Foukakis T
    Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?
    Ann Oncol. 2025 Apr 5:S0923-7534(25)00133-4. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
35. SANTUCCI C, Mignozzi S, Levi F, Malvezzi M, et al
    European cancer mortality predictions for the year 2025 with focus on breast cancer.
    Ann Oncol. 2025;36:460-468.
    PubMed     Abstract available
    
    
    March 2025
36. ZENG X, Sun H, Wang Y
    Letter Re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial".
    Ann Oncol. 2025 Mar 30:S0923-7534(25)00126-7. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
37. LI JJ, Chen L, Shao ZM
    Response letter re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.
    Ann Oncol. 2025 Mar 30:S0923-7534(25)00127-9. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
38. LOIBL S, Martin M, Bonnefoi H, Untch M, et al
    Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B.
    Ann Oncol. 2025 Mar 24:S0923-7534(25)00121-8. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
39. ANDERSEN L, Birkbak NJ
    Advancing ctDNA detection: Using whole-genome sequencing to power minimal residual disease monitoring in breast cancer.
    Ann Oncol. 2025 Mar 20:S0923-7534(25)00114-0. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
40. LI JJ, Wang ZH, Chen L, Zhang WJ, et al
    Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.
    Ann Oncol. 2025 Mar 4:S0923-7534(25)00082-1. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    February 2025
41. GARCIA-MURILLAS I, Abbott CW, Cutts RJ, Boyle SM, et al
    Whole genome sequencing powered ctDNA sequencing for breast cancer detection.
    Ann Oncol. 2025 Feb 4:S0923-7534(25)00053-5. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
42. CARAUSU M, Neven P, Ignatiadis M
    Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial.
    Ann Oncol. 2025;36:127-129.
    PubMed    
    
    
    January 2025
43. ANDRE F, Solovieff N, Su F, Bardia A, et al
    Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
    Ann Oncol. 2025;36:54-64.
    PubMed     Abstract available
    
    
    December 2024
44. FERNANDEZ-MARTINEZ A, Tanioka M, Ahn SG, Zagami P, et al
    Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
    Ann Oncol. 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
45. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
    Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986].
    Ann Oncol. 2024 Dec 2:S0923-7534(24)04882-8. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
46. GOETZ MP, Andre V, Johnston SRD
    Response to letters to the Editor on 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3'.
    Ann Oncol. 2024;35:1202-1204.
    PubMed    
    
    
    November 2024
47. KIM J, Munster PN
    Estrogens and breast cancer.
    Ann Oncol. 2024 Nov 8:S0923-7534(24)04880-4. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    October 2024
48. HUPPERT LA, Wolf D, Yau C, Brown-Swigart L, et al
    Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
49. HORTOBAGYI GN, Lacko A, Sohn J, Cruz F, et al
    A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.
    Ann Oncol. 2024 Oct 21:S0923-7534(24)04064-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
50. MARTIN M, Stecklein SR, Gluz O, Villacampa G, et al
    TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
    Ann Oncol. 2024 Oct 15:S0923-7534(24)04061-4. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
51. COLLIER KA, Stover DG
    Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA.
    Ann Oncol. 2024;35:917-919.
    PubMed    
    
    
    September 2024
52. SAKAI H, Tsurutani J, Ozaki Y, Ishiguro H, et al
    A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtec
    Ann Oncol. 2024 Sep 5:S0923-7534(24)03995-4. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
53. ANDRE F, Cortes J, Curigliano G, Modi S, et al
    A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases.
    Ann Oncol. 2024 Sep 4:S0923-7534(24)03928-0. doi: 10.1016/j.annonc.2024.08.2347.
    PubMed     Abstract available
    
    
    
54. DE SANCTIS R, Bruzzi P, Zambelli A
    Unlocking Methodological Insights on Oncology Efficacy Endpoints: from Statistical to Clinical and Vice Versa. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer
    Ann Oncol. 2024 Sep 3:S0923-7534(24)03925-5. doi: 10.1016/j.annonc.2024.08.2345.
    PubMed    
    
    
    August 2024
55. DI MEGLIO A, Havas J, Pagliuca M, Franzoi MA, et al
    A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later.
    Ann Oncol. 2024 Aug 2:S0923-7534(24)01517-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
56. LOBO-MARTINS S, Agostinetto E, de Azambuja E, Gebhart G, et al
    Tumour Heterogeneity in Molecular Imaging for Breast Cancer.
    Ann Oncol. 2024 Aug 2:S0923-7534(24)01515-1. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
57. SANCHEZ-BAYONA R, Oliveira M
    Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors.
    Ann Oncol. 2024;35:689-691.
    PubMed    
    
    
    
58. MIGLIACCIO I, Biganzoli L, Malorni L
    The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
    Ann Oncol. 2024;35:683-685.
    PubMed    
    
    
    July 2024
59. ROWLANDS CF, Allen S, Balmana J, Domchek SM, et al
    Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
    Ann Oncol. 2024 Jul 8:S0923-7534(24)01014-7. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
60. FREEDMAN RA, Heiling HM, Li T, Trapani D, et al
    Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.
    Ann Oncol. 2024 Jul 6:S0923-7534(24)01015-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
61. TARANTINO P, Tolaney SM
    Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes.
    Ann Oncol. 2024;35:579-581.
    PubMed    
    
    
    June 2024
62. ARECCO L, Bruzzone M, Bas R, Kim HJ, et al
    Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers.
    Ann Oncol. 2024 Jun 20:S0923-7534(24)00740-3. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
63. SHERRY AD, Lin TA, McCaw ZR, Ludmir EB, et al
    Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M.
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00718-X. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
64. ORLANDI A, Mastrantoni L, Bria E, Tortora G, et al
    To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00719-1. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    May 2024
65. HAMILTON E, Oliveira M, Turner N, Garcia-Corbacho J, et al
    A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
    Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
66. GOETZ MP, Toi M, Huober J, Sohn J, et al
    Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
    Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
67. DENT R, Andre F, Goncalves A, Martin M, et al
    IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
    Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
68. PUSZTAI L, Denkert C, O'Shaughnessy J, Cortes J, et al
    Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Ann Oncol. 2024;35:429-436.
    PubMed     Abstract available
    
    
    April 2024
69. PETERS S, Loi S, Andre F, Chandarlapaty S, et al
    Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
    Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    March 2024
70. AGOSTINETTO E, Buisseret L, Salgado R, Kok M, et al
    Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?
    Ann Oncol. 2024 Mar 12:S0923-7534(24)00077-2. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    February 2024
71. GENNARI A, Brain E, De Censi A, Nanni O, et al
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET.
    Ann Oncol. 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.